Sophia Genetics, a Switzerland-based SJE Group investment, has expanded its global partnership with Integrated DNA Technologies; a leading comprehensive genomics solutions provider based in the US.
Together, the superior enrichment products of IDT combined with SOPHiA GENETICS’s universal analytics platform and advanced multimodal solutions, provide powerful solutions for clinical researchers.
When bundling IDT’s reagents with the SOPHiA Platform, researchers will benefit from sophisticated analysis technology and the collective intelligence of the SOPHiA community. It will help accurately detect and characterize genomic variants and share insights in the healthcare ecosystem. In addition, users can also take advantage of the SOPHiA Set-Up Program which is designed to support the implementation of Next-Generation Sequencing (NGS)-based testing for genetic diseases.
IDT and SOPHiA GENETICS have teamed up for a number of years, including the development of a first of its kind In Vitro Diagnostics (IVD) marked SOPHiA Hereditary Cancer Solution in 2016. SOPHiA GENETICS has launched several additional IVD solutions since then, providing simple and fast procedures for healthcare professionals committed to serving patients by bringing clinical diagnostics in-house.
The SJE Group congratulates both IDT and Sophia Genetics on this expanded partnership.
About Sophia Genetics
SOPHiA GENETICS (SG) combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Its mission is to bring data analytics solutions to market, to support healthcare professionals by maximizing the power of Data-Driven Medicine. SG achieve this mission through the global adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients.